Drug Development

Program Feature

Featured Program: E6201, Dual-targeted FLT3 and MEK Inhibitor

Working in collaboration with MD Anderson and Eisai, Strategia is undertaking clinical Proof of Concept (PoC) trials of E6201, a dual-targeted FLT3 and MEK inhibitor, for the high unmet need of FLT3 mutated AML and other cancer indications. This collaborative global team is a prime example of Strategia applying its “True” Open Innovation ® platform to develop drug candidates with potential to significantly improve patient health care. As such, it represents the next step toward Strategia’s vision to create a novel and comprehensive approach to global pharmaceutical development.

Metastatic Melanoma

E6201 was under development by Eisai in metastatic melanoma. Strategia Therapeutics licensed in E6201 in 2014 for all oncology indications and assumed responsibility for the Phase 1 metastatic melanoma trial. The trial is ongoing but closed to enrollment of new patients.

Advanced Hematologic Malignancies

Building on strong scientific rationale supported by new preclinical data from Dr. Gautam Borthakur at University of Texas M.D. Anderson Cancer Center (MDACC), Strategia Therapeutics has begun a Phase 1/2a clinical trial of E6201 in patients with advanced hematologic malignancies, including relapsed or refractory acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being carried out at the University of Texas M.D. Anderson Cancer Center with Gautam Borthakur, M.D., as the Principal Investigator. Please go to Clinicaltrials.gov for more details.

Reference

Zhang W, Borthakur G, Gao C, Chen Y, Lan YS, Ruvolo V, Nomoto K, Zhao N, Konopleva M, Andreeff M. Activity assessment of E6201, a dual FLT3 and MEK inhibitor, in FLT3- or RAS-mutant acute myelogenous leukemia. Blood 2013; Abstr 2683.